BPC-157 peptide.

What is BPC-157?

BPC-157 is a synthetic peptide made from 15 amino acids. Research focuses on joint pain, tendon and ligament healing, muscle recovery, wound closure and protection of the gut lining. [1]

BPC stands for Body Protection Compound. The name comes from research on a protein fragment associated with gastric juice. The BPC-157 used in products is manufactured by peptide synthesis; it is not an extract of stomach tissue or a food ingredient. [1]

Human findings: small clinical studies. Tissue-repair findings: mainly animal and cell research.

How BPC-157 works

BPC-157 changes signals involved in tissue repair. In laboratory tendon samples, repair cells moved out of the tendon more readily and survived better under stress. The experiment linked this activity to FAK and paxillin, proteins that help cells attach and move. [10]

Another experiment found more growth-hormone receptors in rat tendon cells, making those cells more responsive to added growth hormone. That does not make BPC-157 HGH or show that it raises blood HGH levels in humans. It is also a different compound from GLP-1 medicines used for appetite and weight management. [11]

Repair mechanisms and specific tissue findings →

BPC-157 benefits

Benefits for joints, tendons, muscle, gut and skin →

BPC-157 daily dosage

250 mcg once daily totals 250 mcg a day. 250 mcg twice daily totals 500 mcg a day.

Public-use examples; both courses lasted six weeks. Not a prescribed regimen. [2] [3]

A 10 mg vial contains 40 daily portions at 250 mcg, or 20 at 500 mcg. Six weeks at 500 mcg/day totals 21 mg: three whole 10 mg vials or two 15 mg pens, rounded up. These calculations exclude handling losses.

Dosage tables, reconstitution and the vial calculator →

BPC-157 cycle length

Six weeks, or 42 days, was the course length in both sourced examples. [2] [3]

Four and eight weeks are quantity comparisons, not established treatment durations.

Results at weeks 2, 3 and 6 →

Vial, pen, capsules or spray: compare the actual products

10 mg powder vial · 15 mg prefilled pen · 500 mcg capsules · nasal spray. Capsule bottles contain 60 units; the spray’s reference specification is 150 mcg per actuation. [6]

Quantities shown for the four research-labelled products. Spray figures follow the reference specification; confirm the current bottle label. Drawings illustrate the formats; they are not product photographs.

The pen contains 50% more labeled BPC-157 than the 10 mg vial. Each 30 mg bottle contains twice the pen’s total and three times the vial’s total. Total content does not measure absorption or effectiveness.

Storage specifications for these products. Prepared-vial storage is different from sealed-powder storage. [6]

Compare products, storage and COAs →

Oral BPC-157 versus injections

A 500 mcg capsule and a 500 mcg injection are not established equivalent doses. The number gives the amount in the product; it does not tell you how much reaches the bloodstream or injured tissue. Human absorption data do not supply a reliable oral-to-injection conversion. [12]

Convenience is easier to compare than effectiveness: capsules avoid needles, a prefilled pen avoids powder mixing, and a vial requires preparation. Those differences do not establish a clinical winner.

Oral-use results → · Gut-health findings → · Capsule strength and arginate labels →

BPC-157 results and timeline

Shoulder figures: one six-week course with ongoing mobility work. Knee finding: an uncontrolled clinical series. These examples are not an average recovery timetable.

See the full results and recovery timelines →

BPC-157 vs Wolverine: what changes in the blend?

Wolverine combines BPC-157 with TB-500. In a 1:1 blend, half the total is BPC-157 and half is TB-500.

For example, 10 mg BPC-157 + 10 mg TB-500 makes 20 mg total blend. A 500 mcg portion of that 1:1 blend contains 250 mcg of each ingredient. It does not contain 500 mcg of BPC-157. Also check whether a separate GLOW or KLOW product already includes BPC-157 before adding its amount to a stack.

Wolverine blend amounts and BPC-157 stacking →

BPC-157 side effects

Side effects and what to do →

FDA status → · Sport rules and drug testing →

Batch reports: the 10 mg vial and 500 mcg capsules

The attached vial certificate reports 99.74% HPLC area purity for lot PL-2609-010. The capsule certificate reports 99.62% for lot PL-2609-012 and a content assay of 494.7 mcg per capsule. Both are in-house reports for the named sampled lots. [4] [5]

REDACTED COPY · IN-HOUSE REPORT

BPC-157 10 mg vial — lot PL-2609-010

99.74% HPLC area purity

Label amount10 mg / vialLC-MS identity1419.8 Da

Open redacted COA

REDACTED COPY · IN-HOUSE REPORT

BPC-157 capsules — lot PL-2609-012

99.62% HPLC area purity

Content assay494.7 mcg / capsuleLC-MS identity1419.8 Da

Open redacted COA

Purity measures the main compound’s share of the HPLC signal; content measures the amount per capsule. The vial report has no fill-content assay. These two reports cover the named vial and capsule lots, not the pen or spray.

Redacted COAs and batch details →